Literature DB >> 18034586

Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal".

Paula Ghaneh1, Catrin Tudur-Smith, John P Neoptolemos.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18034586     DOI： 10.2165/00003495-200767170-00002

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  21 in total

1.  ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas.

Authors:  Douglas B Evans; Kenneth R Hess; Peter W T Pisters
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

4.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

5.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

6.  One and two sided tests of significance.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1994-07-23

Review 7.  Adjuvant therapy in pancreatic cancer: historical and current perspectives.

Authors:  J P Neoptolemos; D Cunningham; H Friess; C Bassi; D D Stocken; D M Tait; J A Dunn; C Dervenis; F Lacaine; H Hickey; M G T Raraty; P Ghaneh; M W Büchler
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

Review 8.  Adjuvant therapy in pancreatic cancer: a critical appraisal.

Authors:  Helmut Oettle; Peter Neuhaus
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer.

Authors:  Paula Ghaneh; John P Neoptolemos
Journal:  Surg Oncol Clin N Am       Date:  2004-10       Impact factor: 3.495

10.  Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Authors:  D D Stocken; M W Büchler; C Dervenis; C Bassi; H Jeekel; J H G Klinkenbijl; K E Bakkevold; T Takada; H Amano; J P Neoptolemos
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640
View more
  1 in total

1.  Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.

Authors:  Ashiq Masood; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancers (Basel)       Date:  2011-06-01       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.